MedTrace Logo

S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer

NCT00005975 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2015-11-18

No results posted yet for this study

Summary

RATIONALE: Megestrol may be effective in treating hot flashes following treatment for breast cancer. It is not yet known which regimen of megestrol is most effective for hot flashes.

PURPOSE: Randomized phase III trial to compare the effectiveness of different doses of megestrol in treating hot flashes in patients who have undergone therapy for breast cancer.

Conditions

Interventions

DRUG

Megestrol Acetate 20mg/day

Double blinded Megestrol Acetate 20 mg/day

DRUG

Megestrol Acetate 40 mg/day

Double blinded Megestrol Acetate 40 mg/day

DRUG

Megestrol Acetate Placebo 20 mg/day

Megestrol Acetate Placebo 20 mg/day

DRUG

Megestrol Acetate Placebo 40 mg/day

Megestrol Acetate Placebo 40 mg/day

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • John W. Goodwin, MD · Cancer Research for the Ozarks

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2001-09-30
Completion
2002-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005975 on ClinicalTrials.gov